 prolong administr oral etoposid patient relaps refractori small-cel lung cancer phase II trial twenty-two patient recurr small-cel lung cancer sclc single-ag etoposid mouth consecut day eleven patient previou chemotherapi cyclophosphamid doxorubicin vincristin cav etoposid cae cave latter patient salvag treatment cisplatin etoposid EP nine patient EP induct therapi patient high-dos cyclophosphamid cisplatin hdcep patient previou intraven etoposid median time chemotherapi month rang month patient confid interv CI complet partial respons respons common patient previou chemotherapi treatment day initi oral etoposid median respons durat month rang month median surviv month rang month leukocyt platelet nadir cycl treatment day overal total leukocyt count cycl patient hospit neutropenia fever toxic death due platelet cycl alopecia patient gastrointestin toxic uncommon schedul etoposid administr warrant studi combin activ agent untreat patient sclc